|
1
|
Dreosti IE, Wargovich MJ and Yang CS:
Inhibition of carcinogenesis by tea: the evidence from experimental
studies. Crit Rev Food Sci Nutr. 37:761–770. 1997. View Article : Google Scholar
|
|
2
|
Katiyar S and Mukhtar H: Tea in
chemoprevention of cancer. Int J Oncol. 8:221–238. 1996.PubMed/NCBI
|
|
3
|
Yang CS, Maliakal P and Meng X: Inhibition
of carcinogenesis by tea. Annu Rev Pharmacol Toxicol. 42:25–54.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Katiyar SK and Elmets CA: Green tea
polyphenolic antioxidants and skin photoprotection (Review). Int J
Oncol. 18:1307–1313. 2001.PubMed/NCBI
|
|
5
|
Yang CS: Inhibition of carcinogenesis by
tea. Nature. 389:134–135. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang CS and Wang H: Mechanistic issues
concerning cancer prevention by tea catechins. Mol Nutr Food Res.
55:819–831. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ma YC, Li C, Gao F, et al:
Epigallocatechin gallate inhibits the growth of human lung cancer
by directly targeting the EGFR signaling pathway. Oncol Rep.
31:1343–1349. 2014.
|
|
8
|
Maruyama T, Murata S, Nakayama K, et al:
(−)-Epigallocatechin-3-gallate suppresses liver metastasis of human
colorectal cancer. Oncol Rep. 31:625–633. 2014.
|
|
9
|
Bode AM and Dong Z: Epigallocatechin
3-gallate and green tea catechins: united they work, divided they
fail. Cancer Prev Res. 2:514–517. 2009. View Article : Google Scholar
|
|
10
|
Shirakami Y, Shimizu M and Moriwaki H:
Cancer chemoprevention with green tea catechins: from bench to bed.
Curr Drug Targets. 13:1842–1857. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh BN, Shankar S and Srivastava RK:
Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms,
perspectives and clinical applications. Biochem Pharmacol.
82:1807–1821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shimizu M, Shirakami Y and Moriwaki H:
Targeting receptor tyrosine kinases for chemoprevention by green
tea catechin, EGCG. Int J Mol Sci. 9:1034–1049. 2008. View Article : Google Scholar
|
|
13
|
Khoi PN, Park JS, Kim JH, et al:
(−)-Epigallocatechin-3-gallate blocks nicotine-induced matrix
metalloproteinase-9 expression and invasiveness via suppression of
NF-κB and AP-1 in endothelial cells. Int J Oncol. 43:868–876.
2013.PubMed/NCBI
|
|
14
|
Dong Z, Ma W, Huang C and Yang CS:
Inhibition of tumor promoter-induced activator protein 1 activation
and cell transformation by tea polyphenols, (−)-epigallocatechin
gallate, and theaflavins. Cancer Res. 57:4414–4419. 1997.PubMed/NCBI
|
|
15
|
Rouzer CA and Marnett LJ: Green tea gets
molecular. Cancer Prev Res. 4:1343–1345. 2011. View Article : Google Scholar
|
|
16
|
Bode AM and Dong Z: Targeting signal
transduction pathways by chemopreventive agents. Mutat Res.
555:33–51. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jankun J, Selman SH, Swiercz R and
Skrzypczak-Jankun E: Why drinking green tea could prevent cancer.
Nature. 387:5611997. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
He Z, Tang F, Ermakova S, et al: Fyn is a
novel target of (−)-epigallocatechin gallate in the inhibition of
JB6 Cl41 cell transformation. Mol Carcinog. 47:172–183. 2008.
View Article : Google Scholar
|
|
19
|
Sakamoto Y, Terashita N, Muraguchi T,
Fukusato T and Kubota S: Effects of epigallocatechin-3-gallate
(EGCG) on A549 lung cancer tumor growth and angiogenesis. Biosci
Biotechnol Biochem. 77:1799–1803. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Katiyar S, Elmets CA and Katiyar SK: Green
tea and skin cancer: photoimmunology, angiogenesis and DNA repair.
J Nutr Biochem. 18:287–296. 2007. View Article : Google Scholar
|
|
21
|
Scully C and Bagan J: Oral squamous cell
carcinoma overview. Oral Oncol. 45:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shah JP and Gil Z: Current concepts in
management of oral cancer - surgery. Oral Oncol. 45:394–401. 2009.
View Article : Google Scholar
|
|
23
|
Calabrese L, Tagliabue M, Maffini F,
Massaro MA and Santoro L: From wide excision to a compartmental
approach in tongue tumors: what is going on? Curr Opin Otolaryngol
Head Neck Surg. 21:112–117. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuen AP, Lam KY, Chan AC, et al:
Clinicopathological analysis of elective neck dissection for N0
neck of early oral tongue carcinoma. Am J Surg. 177:90–92. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rana M, Iqbal A, Warraich R, Ruecker M,
Eckardt AM and Gellrich NC: Modern surgical management of tongue
carcinoma - a clinical retrospective research over a 12 years
period. Head Neck Oncol. 3:432011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Petersen PE: Global policy for improvement
of oral health in the 21st century - implications to oral health
research of World Health Assembly 2007, World Health Organization.
Community Dent Oral Epidemiol. 37:1–8. 2009. View Article : Google Scholar
|
|
27
|
Preis M, Hadar T, Soudry E, et al: Early
tongue carcinoma: analysis of failure. Head Neck. 34:418–421. 2012.
View Article : Google Scholar
|
|
28
|
Koppenol WH, Bounds PL and Dang CV: Otto
Warburg’s contributions to current concepts of cancer metabolism.
Nat Rev Cancer. 11:325–337. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tennant DA, Durán RV and Gottlieb E:
Targeting metabolic transformation for cancer therapy. Nat Rev
Cancer. 10:267–277. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Denko NC: Hypoxia, HIF1 and glucose
metabolism in the solid tumour. Nat Rev Cancer. 8:705–713. 2008.
View Article : Google Scholar
|
|
32
|
Wallace DC: Mitochondria and cancer:
Warburg addressed. Cold Spring Harb Symp Quant Biol. 70:363–374.
2005. View Article : Google Scholar
|
|
33
|
Ros S and Schulze A: Glycolysis back in
the limelight: systemic targeting of HK2 blocks tumor growth.
Cancer Discov. 3:1105–1107. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Patra KC, Wang Q, Bhaskar PT, et al:
Hexokinase 2 is required for tumor initiation and maintenance and
its systemic deletion is therapeutic in mouse models of cancer.
Cancer Cell. 24:213–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wolf A, Agnihotri S, Micallef J, et al:
Hexokinase 2 is a key mediator of aerobic glycolysis and promotes
tumor growth in human glioblastoma multiforme. J Exp Med.
208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yecies JL and Manning BD: Transcriptional
control of cellular metabolism by mTOR signaling. Cancer Res.
71:2815–2820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fruman DA and Rommel C: PI3K and cancer:
lessons, challenges and opportunities. Nat Rev Drug Discov.
13:140–156. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ribeiro FA, Noguti J, Oshima CT and
Ribeiro DA: Effective targeting of the epidermal growth factor
receptor (EGFR) for treating oral cancer: a promising approach.
Anticancer Res. 34:1547–1552. 2014.PubMed/NCBI
|
|
39
|
Cheung EC, Ludwig RL and Vousden KH:
Mitochondrial localization of TIGAR under hypoxia stimulates HK2
and lowers ROS and cell death. Proc Natl Acad Sci USA.
109:20491–20496. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pastorino JG, Shulga N and Hoek JB:
Mitochondrial binding of hexokinase II inhibits Bax-induced
cytochrome c release and apoptosis. J Biol Chem. 277:7610–7618.
2002. View Article : Google Scholar
|
|
41
|
Majewski N, Nogueira V, Bhaskar P, et al:
Hexokinase-mitochondria interaction mediated by Akt is required to
inhibit apoptosis in the presence or absence of Bax and Bak. Mol
Cell. 16:819–830. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Krasnov GS, Dmitriev AA, Lakunina VA,
Kirpiy AA and Kudryavtseva AV: Targeting VDAC-bound hexokinase II:
a promising approach for concomitant anti-cancer therapy. Expert
Opin Ther Targets. 17:1221–1233. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Elattar TM and Virji AS: Effect of tea
polyphenols on growth of oral squamous carcinoma cells in vitro.
Anticancer Res. 20:3459–3465. 2000.PubMed/NCBI
|
|
44
|
Moreira L, Araújo I, Costa T, et al:
Quercetin and epigallocatechin gallate inhibit glucose uptake and
metabolism by breast cancer cells by an estrogen
receptor-independent mechanism. Exp Cell Res. 319:1784–1795. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ueda M, Nishiumi S, Nagayasu H, Fukuda I,
Yoshida K and Ashida H: Epigallocatechin gallate promotes GLUT4
translocation in skeletal muscle. Biochem Biophys Res Commun.
377:286–290. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ku HC, Tsuei YW, Kao CC, et al: Green tea
(−)-epigallocatechin gallate suppresses IGF-I and IGF-II
stimulation of 3T3-L1 adipocyte glucose uptake via the glucose
transporter 4, but not glucose transporter 1 pathway. Gen Comp
Endocrinol. 199:46–55. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Naftalin RJ, Afzal I, Cunningham P, et al:
Interactions of androgens, green tea catechins and the antiandrogen
flutamide with the external glucose-binding site of the human
erythrocyte glucose transporter GLUT1. Br J Pharmacol. 140:487–499.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ongkeko WM, Altuna X, Weisman RA and
Wang-Rodriguez J: Expression of protein tyrosine kinases in head
and neck squamous cell carcinomas. Am J Clin Pathol. 124:71–76.
2005. View Article : Google Scholar : PubMed/NCBI
|
